GE Healthcare is presenting a new cyclotron platform and celebrating the installation of its 500th cyclotron at this week's annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.
The vendor has introduced a new cyclotron Solid Target Platform for its PETtrace cyclotron aimed at increasing production and access to gallium-68, a radiopharmaceutical used for diagnosis, staging, and monitoring of prostate cancer. In combination with its FASTlab 2 New Edition platform, it can produce 100 times the amount of gallium-68 compared with a generator, enabling increased theranostics capabilities, GE said.
GE is also celebrating the 500th installation of its cyclotron.
In other news, GE is also now shipping its Discovery MI Gen 2 premium digital PET/CT system. First showcased at the 2020 RSNA meeting, Discovery MI Gen 2 offers an axial field of view scalable up to 30 centimeters, producing a 125% increase in sensitivity and a 33% improvement in scan times or dose, according to GE.
